BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...Ltd. have the NF-κB inhibitor S-414114 in Phase II testing to treat dermatitis. AnGes and Nippon Zoki Pharmaceutical Co. Ltd....
BioCentury | Apr 8, 2013
Company News

AnGes, Nippon Zoki Pharmaceutical deal

...Japan). The partners could not be reached for details. AnGes MG Inc. (Tokyo:4563), Osaka, Japan Nippon Zoki Pharmaceutical Co. Ltd....
BioCentury | Apr 8, 2013
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

Following a March 2012 evaluation deal, the companies partnered to develop Phosphagenics' topical TPM/diclofenac to treat acute and chronic pain in the U.S. The companies partnered last year to allow Nippon to evaluate the product...
BioCentury | Mar 12, 2012
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

The companies entered into an agreement to allow Nippon to evaluate Phosphagenics' topical TPM/diclofenac to treat pain. If successful, the companies intend to enter into a deal granting the pharma rights to the transdermal gel...
Items per page:
1 - 4 of 4
BioCentury | Oct 10, 2017
Distillery Therapeutics

Neurology

...Ltd. have the NF-κB inhibitor S-414114 in Phase II testing to treat dermatitis. AnGes and Nippon Zoki Pharmaceutical Co. Ltd....
BioCentury | Apr 8, 2013
Company News

AnGes, Nippon Zoki Pharmaceutical deal

...Japan). The partners could not be reached for details. AnGes MG Inc. (Tokyo:4563), Osaka, Japan Nippon Zoki Pharmaceutical Co. Ltd....
BioCentury | Apr 8, 2013
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

Following a March 2012 evaluation deal, the companies partnered to develop Phosphagenics' topical TPM/diclofenac to treat acute and chronic pain in the U.S. The companies partnered last year to allow Nippon to evaluate the product...
BioCentury | Mar 12, 2012
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

The companies entered into an agreement to allow Nippon to evaluate Phosphagenics' topical TPM/diclofenac to treat pain. If successful, the companies intend to enter into a deal granting the pharma rights to the transdermal gel...
Items per page:
1 - 4 of 4